Impact of upfront adjuvant chemoradiation on survival in patients with molecularly defined oligodendroglioma: the benefits of PCV over TMZ.
1p/19q codeletion
IDH mutant
Molecular oligodendroglioma
PCV
Temozolomide
Journal
Journal of neuro-oncology
ISSN: 1573-7373
Titre abrégé: J Neurooncol
Pays: United States
ID NLM: 8309335
Informations de publication
Date de publication:
09 Oct 2024
09 Oct 2024
Historique:
received:
26
07
2024
accepted:
10
09
2024
medline:
9
10
2024
pubmed:
9
10
2024
entrez:
9
10
2024
Statut:
aheadofprint
Résumé
Oligodendroglioma is an adult-type diffuse glioma defined by 1p/19q codeletion and IDH1/2 mutation. Treatment includes surgery followed by observation alone in select low-grade tumors, or combination radiation and chemotherapy with procarbazine, lomustine, and vincristine (PCV) or temozolomide (TMZ). While prospective studies investigating treatments for molecularly defined oligodendrogliomas are ongoing, this retrospective study analyzes the relationship between adjuvant regimens and progression-free survival (PFS). Adults with IDH-mutant, 1p/19q codeleted oligodendroglioma (WHO grade 2 or 3) who underwent surgery between 2005 and 2021 were identified. Clinical data, disease characteristics, treatment, and outcomes were collected. A total of 207 patients with grade 2 and 70 with grade 3 oligodendrogliomas were identified. Median (IQR) follow-up was 57 (87) months. Patients with grade 3 tumors who received adjuvant radiation and PCV had longer median PFS (> 110 months) than patients who received radiation and TMZ (52 months, p = 0.008) or no adjuvant chemoradiation (83 months, p = 0.03), which was not seen in grade 2 tumors (p = 0.8). In multivariate analysis, patients who received PCV chemotherapy (Relative Risk [95% CI] = 0.24[0.05-1.08] and radiotherapy (0.46[0.21-1.02]) trended towards longer PFS, independently of grade. Adjuvant radiation and PCV are associated with improved PFS over radiation with TMZ in patients with grade 3 molecularly defined oligodendrogliomas, and all-grade patients treated with PCV trended towards decreased risk of recurrence and progression. These results highlight the importance of ongoing clinical trials investigating these treatments.
Identifiants
pubmed: 39382617
doi: 10.1007/s11060-024-04829-6
pii: 10.1007/s11060-024-04829-6
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NINDS NIH HHS
ID : 5R25NS065729
Pays : United States
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Ostrom QT, Shoaf ML, Cioffi G, Waite K, Kruchko C, Wen PY, Brat DJ, Barnholtz-Sloan JS, Iorgulescu JB (2023) National-level overall survival patterns for molecularly-defined diffuse glioma types in the United States. Neuro Oncol 25:799–807. https://doi.org/10.1093/neuonc/noac198
doi: 10.1093/neuonc/noac198
pubmed: 35994777
Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, Hawkins C, Ng HK, Pfister SM, Reifenberger G, Soffietti R, von Deimling A, Ellison DW (2021) The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol 23:1231–1251. https://doi.org/10.1093/neuonc/noab106
doi: 10.1093/neuonc/noab106
pubmed: 34185076
pmcid: 8328013
Rincon-Torroella J, Rakovec M, Materi J, Raj D, Vivas-Buitrago T, Ferres A, Reyes Serpa W, Redmond KJ, Holdhoff M, Bettegowda C, Gonzalez Sanchez JJ (2022) Current and future frontiers of molecularly defined oligodendrogliomas. Front Oncol 12:934426. https://doi.org/10.3389/fonc.2022.934426
doi: 10.3389/fonc.2022.934426
pubmed: 35957904
pmcid: 9358027
Wesseling P, van den Bent M, Perry A (2015) Oligodendroglioma: pathology, molecular mechanisms and markers. Acta Neuropathol 129:809–827. https://doi.org/10.1007/s00401-015-1424-1
doi: 10.1007/s00401-015-1424-1
pubmed: 25943885
pmcid: 4436696
Van den Bent MJ, Reni M, Gatta G, Vecht C (2008) Oligodendroglioma. Crit Rev Oncol Hematol 66:262–272. https://doi.org/10.1016/j.critrevonc.2007.11.007
doi: 10.1016/j.critrevonc.2007.11.007
pubmed: 18272388
Eckel-Passow JE, Lachance DH, Molinaro AM, Walsh KM, Decker PA, Sicotte H, Pekmezci M, Rice T, Kosel ML, Smirnov IV, Sarkar G, Caron AA, Kollmeyer TM, Praska CE, Chada AR, Halder C, Hansen HM, McCoy LS, Bracci PM, Marshall R, Zheng S, Reis GF, Pico AR, O’Neill BP, Buckner JC, Giannini C, Huse JT, Perry A, Tihan T, Berger MS, Chang SM, Prados MD, Wiemels J, Wiencke JK, Wrensch MR, Jenkins RB (2015) Glioma groups based on 1p/19q, IDH, and TERT promoter mutations in tumors. N Engl J Med 372:2499–2508. https://doi.org/10.1056/NEJMoa1407279
doi: 10.1056/NEJMoa1407279
pubmed: 26061753
pmcid: 4489704
Cancer Genome Atlas Research N, Brat DJ, Verhaak RG, Aldape KD, Yung WK, Salama SR, Cooper LA, Rheinbay E, Miller CR, Vitucci M, Morozova O, Robertson AG, Noushmehr H, Laird PW, Cherniack AD, Akbani R, Huse JT, Ciriello G, Poisson LM, Barnholtz-Sloan JS, Berger MS, Brennan C, Colen RR, Colman H, Flanders AE, Giannini C, Grifford M, Iavarone A, Jain R, Joseph I, Kim J, Kasaian K, Mikkelsen T, Murray BA, O'Neill BP, Pachter L, Parsons DW, Sougnez C, Sulman EP, Vandenberg SR, Van Meir EG, von Deimling A, Zhang H, Crain D, Lau K, Mallery D, Morris S, Paulauskis J, Penny R, Shelton T, Sherman M, Yena P, Black A, Bowen J, Dicostanzo K, Gastier-Foster J, Leraas KM, Lichtenberg TM, Pierson CR, Ramirez NC, Taylor C, Weaver S, Wise L, Zmuda E, Davidsen T, Demchok JA, Eley G, Ferguson ML, Hutter CM, Mills Shaw KR, Ozenberger BA, Sheth M, Sofia HJ, Tarnuzzer R, Wang Z, Yang L, Zenklusen JC, Ayala B, Baboud J, Chudamani S, Jensen MA, Liu J, Pihl T, Raman R, Wan Y, Wu Y, Ally A, Auman JT, Balasundaram M, Balu S, Baylin SB, Beroukhim R, Bootwalla MS, Bowlby R, Bristow CA, Brooks D, Butterfield Y, Carlsen R, Carter S, Chin L, Chu A, Chuah E, Cibulskis K, Clarke A, Coetzee SG, Dhalla N, Fennell T, Fisher S, Gabriel S, Getz G, Gibbs R, Guin R, Hadjipanayis A, Hayes DN, Hinoue T, Hoadley K, Holt RA, Hoyle AP, Jefferys SR, Jones S, Jones CD, Kucherlapati R, Lai PH, Lander E, Lee S, Lichtenstein L, Ma Y, Maglinte DT, Mahadeshwar HS, Marra MA, Mayo M, Meng S, Meyerson ML, Mieczkowski PA, Moore RA, Mose LE, Mungall AJ, Pantazi A, Parfenov M, Park PJ, Parker JS, Perou CM, Protopopov A, Ren X, Roach J, Sabedot TS, Schein J, Schumacher SE, Seidman JG, Seth S, Shen H, Simons JV, Sipahimalani P, Soloway MG, Song X, Sun H, Tabak B, Tam A, Tan D, Tang J, Thiessen N, Triche T, Jr., Van Den Berg DJ, Veluvolu U, Waring S, Weisenberger DJ, Wilkerson MD, Wong T, Wu J, Xi L, Xu AW, Yang L, Zack TI, Zhang J, Aksoy BA, Arachchi H, Benz C, Bernard B, Carlin D, Cho J, DiCara D, Frazer S, Fuller GN, Gao J, Gehlenborg N, Haussler D, Heiman DI, Iype L, Jacobsen A, Ju Z, Katzman S, Kim H, Knijnenburg T, Kreisberg RB, Lawrence MS, Lee W, Leinonen K, Lin P, Ling S, Liu W, Liu Y, Liu Y, Lu Y, Mills G, Ng S, Noble MS, Paull E, Rao A, Reynolds S, Saksena G, Sanborn Z, Sander C, Schultz N, Senbabaoglu Y, Shen R, Shmulevich I, Sinha R, Stuart J, Sumer SO, Sun Y, Tasman N, Taylor BS, Voet D, Weinhold N, Weinstein JN, Yang D, Yoshihara K, Zheng S, Zhang W, Zou L, Abel T, Sadeghi S, Cohen ML, Eschbacher J, Hattab EM, Raghunathan A, Schniederjan MJ, Aziz D, Barnett G, Barrett W, Bigner DD, Boice L, Brewer C, Calatozzolo C, Campos B, Carlotti CG, Jr., Chan TA, Cuppini L, Curley E, Cuzzubbo S, Devine K, DiMeco F, Duell R, Elder JB, Fehrenbach A, Finocchiaro G, Friedman W, Fulop J, Gardner J, Hermes B, Herold-Mende C, Jungk C, Kendler A, Lehman NL, Lipp E, Liu O, Mandt R, McGraw M, McLendon R, McPherson C, Neder L, Nguyen P, Noss A, Nunziata R, Ostrom QT, Palmer C, Perin A, Pollo B, Potapov A, Potapova O, Rathmell WK, Rotin D, Scarpace L, Schilero C, Senecal K, Shimmel K, Shurkhay V, Sifri S, Singh R, Sloan AE, Smolenski K, Staugaitis SM, Steele R, Thorne L, Tirapelli DP, Unterberg A, Vallurupalli M, Wang Y, Warnick R, Williams F, Wolinsky Y, Bell S, Rosenberg M, Stewart C, Huang F, Grimsby JL, Radenbaugh AJ, Zhang J (2015) Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N Engl J Med 372:2481–2498. https://doi.org/10.1056/NEJMoa1402121
Carstam L, Latini F, Solheim O, Bartek J Jr., Pedersen LK, Zetterling M, Beniaminov S, Sjavik K, Ryttlefors M, Jensdottir M, Rydenhag B, Smits A, Jakola AS (2023) Long-term follow up of patients with WHO grade 2 oligodendroglioma. J Neurooncol 164:65–74. https://doi.org/10.1007/s11060-023-04368-6
doi: 10.1007/s11060-023-04368-6
pubmed: 37603235
pmcid: 10462563
Weber-Levine C, Rakovec M, Jiang K, Kalluri A, Raj D, Parker M, Materi J, Sepehri S, Ferres A, Schreck KC, Aldecoa I, Lucas CG, Redmond KJ, Holdhoff M, Sair HI, Weingart JD, Brem H, Gonzalez Sanchez J, Ye X, Bettegowda C, Rincon-Torroella J (2024) Genomic alterations in molecularly defined Oligodendrogliomas. Neurosurgery. https://doi.org/10.1227/neu.0000000000003078
doi: 10.1227/neu.0000000000003078
pubmed: 39007559
Appay R, Dehais C, Maurage CA, Alentorn A, Carpentier C, Colin C, Ducray F, Escande F, Idbaih A, Kamoun A, Marie Y, Mokhtari K, Tabouret E, Trabelsi N, Uro-Coste E, Delattre JY, Figarella-Branger D, Network P (2019) CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas. Neuro Oncol 21:1519–1528. https://doi.org/10.1093/neuonc/noz124
doi: 10.1093/neuonc/noz124
pubmed: 31832685
pmcid: 7145561
World Health O, International Agency for Research on C, Board WHOCoTE (2021) Central nervous system tumours. International Agency for Research on Cancer, World Health Organization, Lyon
Penas-Prado M, Wu J, Cahill DP, Brat DJ, Costello JF, Kluetz PG, Cairncross JG, van den Bent M, Verhaak RGW, Aboud O, Burger P, Chang SM, Cordova C, Huang RY, Rowe LS, Taphoorn MJB, Gilbert MR, Armstrong TS, Workshop N-CO (2020) Proceedings of the comprehensive oncology network evaluating rare CNS tumors (NCI-CONNECT) oligodendroglioma workshop. Neurooncol Adv 2: vdz048 https://doi.org/10.1093/noajnl/vdz048
Dono A, Alfaro-Munoz K, Yan Y, Lopez-Garcia CA, Soomro Z, Williford G, Takayasu T, Robell L, Majd NK, de Groot J, Esquenazi Y, Kamiya-Matsuoka C, Ballester LY (2022) Molecular, histological, and clinical characteristics of oligodendrogliomas: a multi-institutional retrospective study. Neurosurgery 90:515–522. https://doi.org/10.1227/neu.0000000000001875
doi: 10.1227/neu.0000000000001875
pubmed: 35179134
Kinslow CJ, Garton ALA, Rae AI, Marcus LP, Adams CM, McKhann GM, Sisti MB, Connolly ES, Bruce JN, Neugut AI, Sonabend AM, Canoll P, Cheng SK, Wang TJC (2019) Extent of resection and survival for oligodendroglioma: a U.S. population-based study. J Neurooncol 144:591–601. https://doi.org/10.1007/s11060-019-03261-5
doi: 10.1007/s11060-019-03261-5
pubmed: 31407129
Garton ALA, Kinslow CJ, Rae AI, Mehta A, Pannullo SC, Magge RS, Ramakrishna R, McKhann GM, Sisti MB, Bruce JN, Canoll P, Cheng SK, Sonabend AM, Wang TJC (2020) Extent of resection, molecular signature, and survival in 1p19q-codeleted gliomas. J Neurosurg 134:1357–1367. https://doi.org/10.3171/2020.2.JNS192767
doi: 10.3171/2020.2.JNS192767
pubmed: 32384274
Snyder LA, Wolf AB, Oppenlander ME, Bina R, Wilson JR, Ashby L, Brachman D, Coons SW, Spetzler RF, Sanai N (2014) The impact of extent of resection on malignant transformation of pure oligodendrogliomas. J Neurosurg 120:309–314. https://doi.org/10.3171/2013.10.JNS13368
doi: 10.3171/2013.10.JNS13368
pubmed: 24313617
Thon N, Kreth FW, Tonn JC (2015) The role of surgery in grade II/III oligodendroglial tumors. CNS Oncol 4:317–323. https://doi.org/10.2217/cns.15.26
doi: 10.2217/cns.15.26
pubmed: 26478133
pmcid: 6082329
Weller M, van den Bent M, Preusser M, Le Rhun E, Tonn JC, Minniti G, Bendszus M, Balana C, Chinot O, Dirven L, French P, Hegi ME, Jakola AS, Platten M, Roth P, Ruda R, Short S, Smits M, Taphoorn MJB, von Deimling A, Westphal M, Soffietti R, Reifenberger G, Wick W (2021) EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood. Nat Rev Clin Oncol 18:170–186. https://doi.org/10.1038/s41571-020-00447-z
doi: 10.1038/s41571-020-00447-z
pubmed: 33293629
Horbinski C, Nabors LB, Portnow J, Baehring J, Bhatia A, Bloch O, Brem S, Butowski N, Cannon DM, Chao S, Chheda MG, Fabiano AJ, Forsyth P, Gigilio P, Hattangadi-Gluth J, Holdhoff M, Junck L, Kaley T, Merrell R, Mrugala MM, Nagpal S, Nedzi LA, Nevel K, Nghiemphu PL, Parney I, Patel TR, Peters K, Puduvalli VK, Rockhill J, Rusthoven C, Shonka N, Swinnen LJ, Weiss S, Wen PY, Willmarth NE, Bergman MA, Darlow S (2023) NCCN guidelines(R) insights: central nervous system cancers, version 2.2022. J Natl Compr Canc Netw 21:12–20. https://doi.org/10.6004/jnccn.2023.0002
doi: 10.6004/jnccn.2023.0002
pubmed: 36634606
Jaeckle KA, Ballman KV, van den Bent M, Giannini C, Galanis E, Brown PD, Jenkins RB, Cairncross JG, Wick W, Weller M, Aldape KD, Dixon JG, Anderson SK, Cerhan JH, Wefel JS, Klein M, Grossman SA, Schiff D, Raizer JJ, Dhermain F, Nordstrom DG, Flynn PJ, Vogelbaum MA (2021) CODEL: phase III study of RT, RT + TMZ, or TMZ for newly diagnosed 1p/19q codeleted oligodendroglioma. Analysis from the initial study design. Neuro Oncol 23:457–467. https://doi.org/10.1093/neuonc/noaa168
doi: 10.1093/neuonc/noaa168
pubmed: 32678879
van den Bent MJ, Brandes AA, Taphoorn MJ, Kros JM, Kouwenhoven MC, Delattre JY, Bernsen HJ, Frenay M, Tijssen CC, Grisold W, Sipos L, Enting RH, French PJ, Dinjens WN, Vecht CJ, Allgeier A, Lacombe D, Gorlia T, Hoang-Xuan K (2013) Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. J Clin Oncol 31:344–350. https://doi.org/10.1200/JCO.2012.43.2229
doi: 10.1200/JCO.2012.43.2229
pubmed: 23071237
Cairncross G, Wang M, Shaw E, Jenkins R, Brachman D, Buckner J, Fink K, Souhami L, Laperriere N, Curran W, Mehta M (2013) Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. J Clin Oncol 31:337–343. https://doi.org/10.1200/JCO.2012.43.2674
doi: 10.1200/JCO.2012.43.2674
pubmed: 23071247
NCT00978458: Radiation therapy with or without temozolomide in treating patients with low-grade glioma. Bethesda (MD): National Library of Medicine (US), 2024
NCT00887146: Radiation therapy with concomitant and adjuvant temozolomide versus radiation therapy with adjuvant PCV chemotherapy in patients with anaplastic glioma or low grade glioma. Bethesda (MD), 2024
NCT02444000: gliomasPCV only in 1p/19q codeleted anaplastic gliomas (POLCA). Bethesda (MD), 2022
Mohile NA, Messersmith H, Gatson NT, Hottinger AF, Lassman A, Morton J, Ney D, Nghiemphu PL, Olar A, Olson J, Perry J, Portnow J, Schiff D, Shannon A, Shih HA, Strowd R, van den Bent M, Ziu M, Blakeley J (2022) Therapy for diffuse astrocytic and oligodendroglial tumors in adults: ASCO-SNO guideline. J Clin Oncol 40:403–426. https://doi.org/10.1200/JCO.21.02036
doi: 10.1200/JCO.21.02036
pubmed: 34898238
Subramaniam S, Aalberg JJ, Soriano RP, Divino CM (2018) New 5-factor modified frailty index using American College of Surgeons NSQIP data. J Am Coll Surg 226: 173–181 e178 https://doi.org/10.1016/j.jamcollsurg.2017.11.005
Weller J, Katzendobler S, Karschnia P, Lietke S, Egensperger R, Thon N, Weller M, Suchorska B, Tonn JC (2021) PCV chemotherapy alone for WHO grade 2 oligodendroglioma: prolonged disease control with low risk of malignant progression. J Neurooncol 153:283–291. https://doi.org/10.1007/s11060-021-03765-z
doi: 10.1007/s11060-021-03765-z
pubmed: 33932195
pmcid: 8211617
van den Bent MJ, Afra D, de Witte O, Ben Hassel M, Schraub S, Hoang-Xuan K, Malmstrom PO, Collette L, Pierart M, Mirimanoff R, Karim AB, Radiotherapy E, Brain Tumor G, the UKMRC (2005) Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet 366:985–990. https://doi.org/10.1016/S0140-6736(05)67070-5
doi: 10.1016/S0140-6736(05)67070-5
pubmed: 16168780
Buckner JC, Shaw EG, Pugh SL, Chakravarti A, Gilbert MR, Barger GR, Coons S, Ricci P, Bullard D, Brown PD, Stelzer K, Brachman D, Suh JH, Schultz CJ, Bahary JP, Fisher BJ, Kim H, Murtha AD, Bell EH, Won M, Mehta MP, Curran WJ Jr (2016) Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma. N Engl J Med 374:1344–1355. https://doi.org/10.1056/NEJMoa1500925
doi: 10.1056/NEJMoa1500925
pubmed: 27050206
pmcid: 5170873
Yeboa DN, Yu JB, Liao E, Huse J, Penas-Prado M, Kann BH, Sulman E, Grosshans D, Contessa J (2019) Differences in patterns of care and outcomes between grade II and grade III molecularly defined 1p19q co-deleted gliomas. Clin Transl Radiat Oncol 15:46–52. https://doi.org/10.1016/j.ctro.2018.12.003
doi: 10.1016/j.ctro.2018.12.003
pubmed: 30656222
Lassman AB, Hoang-Xuan K, Polley MC, Brandes AA, Cairncross JG, Kros JM, Ashby LS, Taphoorn MJB, Souhami L, Dinjens WNM, Laack NN, Kouwenhoven MCM, Fink KL, French PJ, Macdonald DR, Lacombe D, Won M, Gorlia T, Mehta MP, van den Bent MJ (2022) Joint final report of EORTC 26951 and RTOG 9402: phase III trials with procarbazine, lomustine, and vincristine chemotherapy for anaplastic oligodendroglial tumors. J Clin Oncol 40:2539–2545. https://doi.org/10.1200/JCO.21.02543
doi: 10.1200/JCO.21.02543
pubmed: 35731991
pmcid: 9362869
Bell EH, Zhang P, Shaw EG, Buckner JC, Barger GR, Bullard DE, Mehta MP, Gilbert MR, Brown PD, Stelzer KJ, McElroy JP, Fleming JL, Timmers CD, Becker AP, Salavaggione AL, Liu Z, Aldape K, Brachman DG, Gertler SZ, Murtha AD, Schultz CJ, Johnson D, Laack NN, Hunter GK, Crocker IR, Won M, Chakravarti A (2020) Comprehensive genomic analysis in NRG Oncology/RTOG 9802: a phase III trial of radiation versus radiation plus procarbazine, lomustine (CCNU), and vincristine in high-risk low-grade glioma. J Clin Oncol 38:3407–3417. https://doi.org/10.1200/JCO.19.02983
doi: 10.1200/JCO.19.02983
pubmed: 32706640
pmcid: 7527157
Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO, European Organisation for R, Treatment of Cancer Brain T, Radiotherapy G, National Cancer Institute of Canada Clinical Trials G (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996 https://doi.org/10.1056/NEJMoa043330
van den Bent MJ, Tesileanu CMS, Wick W, Sanson M, Brandes AA, Clement PM, Erridge S, Vogelbaum MA, Nowak AK, Baurain JF, Mason WP, Wheeler H, Chinot OL, Gill S, Griffin M, Rogers L, Taal W, Ruda R, Weller M, McBain C, Reijneveld J, Enting RH, Caparrotti F, Lesimple T, Clenton S, Gijtenbeek A, Lim E, Herrlinger U, Hau P, Dhermain F, de Heer I, Aldape K, Jenkins RB, Dubbink HJ, Kros JM, Wesseling P, Nuyens S, Golfinopoulos V, Gorlia T, French P, Baumert BG (2021) Adjuvant and concurrent temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053–22054): second interim analysis of a randomised, open-label, phase 3 study. Lancet Oncol 22:813–823. https://doi.org/10.1016/S1470-2045(21)00090-5
doi: 10.1016/S1470-2045(21)00090-5
pubmed: 34000245
pmcid: 8191233
Hwang K, Kim TM, Park CK, Chang JH, Jung TY, Kim JH, Nam DH, Kim SH, Yoo H, Hong YK, Kim EY, Lee DE, Joo J, Kim YJ, Choe G, Choi BS, Kang SG, Kim JH, Kim CY (2020) Concurrent and adjuvant temozolomide for newly diagnosed grade III gliomas without 1p/19q co-deletion: a randomized, open-label, phase 2 study (KNOG-1101 study). Cancer Res Treat 52:505–515. https://doi.org/10.4143/crt.2019.421
doi: 10.4143/crt.2019.421
pubmed: 31671938
Lamba N, McAvoy M, Kavouridis VK, Smith TR, Touat M, Reardon DA, Iorgulescu JB (2022) Short-term outcomes associated with temozolomide or PCV chemotherapy for 1p/19q-codeleted WHO grade 3 oligodendrogliomas: a national evaluation. Neurooncol Pract 9:201–207. https://doi.org/10.1093/nop/npac004
doi: 10.1093/nop/npac004
pubmed: 35601971
pmcid: 9113268
Lassman AB, Iwamoto FM, Cloughesy TF, Aldape KD, Rivera AL, Eichler AF, Louis DN, Paleologos NA, Fisher BJ, Ashby LS, Cairncross JG, Roldan GB, Wen PY, Ligon KL, Schiff D, Robins HI, Rocque BG, Chamberlain MC, Mason WP, Weaver SA, Green RM, Kamar FG, Abrey LE, DeAngelis LM, Jhanwar SC, Rosenblum MK, Panageas KS (2011) International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors. Neuro Oncol 13:649–659. https://doi.org/10.1093/neuonc/nor040
doi: 10.1093/neuonc/nor040
pubmed: 21636710
pmcid: 3107101
Bush NAO, Young JS, Zhang Y, Dalle Ore CL, Molinaro AM, Taylor J, Clarke J, Prados M, Braunstein SE, Raleigh DR, Chang SM, Berger MS, Butowski NA (2021) A single institution retrospective analysis on survival based on treatment paradigms for patients with anaplastic oligodendroglioma. J Neurooncol 153:447–454. https://doi.org/10.1007/s11060-021-03781-z
doi: 10.1007/s11060-021-03781-z
pubmed: 34125374
pmcid: 8279971